Spherix’s Type 2 diabetes drug caused ‘significant drop’ in patients’ HbA1c levels
BETHESDA, Md. Relatively healthy patients with Type 2 diabetes experienced a significant reduction in blood-sugar levels when taking an investigational treatment for Type 2 diabetes made by Spherix, the biotechnology company said Thursday.
Spherix announced results of a phase-3 trial of D-tagatose, which showed that the drug was more effective in American patients than in Indian patients.
“These are promising results, and we are pleased with the significant drop in HbA1c levels among patients treated with D-tagatose,” Spherix CEO Claire Kruger said. “As a monotherapy in a patient population with mild disease, this achievement is even more compelling.”
NCPA to CMS: Medicaid reimbursements should adhere to healthcare-reform law provisions
ALEXANDRIA, Va. The National Community Pharmacists Association is urging the Centers for Medicare and Medicaid Services to follow guidance that Congress included in the healthcare-reform law in its implementation of a new Medicaid generic drug reimbursement formula based on average manufacturer price, the organization said Tuesday.
CMS recently withdrew provisions that would have dramatically cut Medicaid pharmacy reimbursement to community pharmacies from a previously proposed AMP rule due to an injunction that the NCPA obtained in 2007.
In a letter to Congress, the NCPA recommended giving manufacturers more direction in calculating their AMPs, such as requiring them to only include prices paid by wholesalers for drugs subsequently sold at pharmacies; recognizing the ill effect that the NCPA said curtailed generic drug reimbursements would have on retail pharmacies; and setting up a process by which revised federal upper limits resulting from the revised AMP data will be implemented in order to minimize disruption for patients and pharmacies.
“In many ways, independent community pharmacies are the backbone of Medicaid’s prescription drug benefit,” NCPA acting EVP and CEO Douglas Hoey said. “Pharmacies will become an even more important source of health care-related services for Medicaid beneficiaries as new healthcare reform provisions are implemented.”
David Brailer joins Walgreens’ board of directors
DEERFIELD, Ill. Walgreens has appointed the chairman of Health Evolution Partners to its board of directors.
The drug store chain announced Wednesday that David Brailer would join Walgreens’ board as an independent director, making him the board’s 11th member.
Brailer has served as chairman of Health Evolution Partners since 2006. Prior to joining Health Evolution Partners, he was appointed by the Bush administration as the first national health-information technology coordinator in 2004.
“David’s expertise in advancing healthcare technology on a national level, as well as his experience in supporting companies through investments that promote major change in the health system will provide us with valuable insight,” said Walgreens chairman Alan McNally. “This will be extremely important in the years ahead as technology plays an even greater role in the delivery of quality, affordable and accessible health care.”
Walgreens president and CEO Greg Wasson added, “David will be a tremendous resource to our board and our company as we help patients and payers lower healthcare costs while improving quality, outcomes and transparency through our pharmacy, health and wellness solutions.”